[A18-63] Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Last updated 22.03.2019
Project no.:
A18-63
Commission:
Commission awarded on 01.08.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer after prior endocrine therapy
PALOMA-3 study unsuitable for the derivation of an added benefit due to inadequate implementation of appropriate comparator therapy; added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-14 | Palbociclib (breast cancer) - Addendum to Commission A18-63 | Commission completed |
| A16-74 | Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-66 | Palbociclib (breast cancer) – Benefit assessment according to § 35a SGB V | Commission completed |
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.